IQVIA Holdings Inc. (IQV) had an impressive run in the past three months. The company's shares have gained 12.5% compared with the 3.4% rally of its industry and the 2.5% rise of the Zacks S&P 500 composite. IQV reported impressive second-quarter 2024 results. Adjusted earnings (excluding 67 cents from nonrecurring items) were $2.6 per share, outpacing the Zacks Consensus Estimate by 2.3% and increasing 2.4% on a year-over-year basis. Total revenues of $3.8 billion surpassed the consensus estimate marginall ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solu ...

It has been about a month since the last earnings report for IQVIA Holdings (IQV) . Shares have added about 3.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. IQVIA Surpasses Q2 Earnings Estimates IQVIA Holdin ...

I I F ■ F Matteo Colombo Investment update Following my May publication on IQVIA Holdings Inc. (NYSE:IQV) the stock is +5%, marking a 28% return since I first rated the business investment-grade back in Jan '21. This is a business I know tremendously well, having analyzed its credentials for more than 3 years and owned the stock for our equity budget for that entire duration. In the five publications I've made on IQV here on SA since then, my views have not changed on this long-term compounder. Following it ...

Core Insights - IQVIA Holdings Inc. (IQV) shares have increased by 12% over the past year, outperforming the industry growth of 10% [1] - The company has a projected long-term EPS growth rate of 10.4%, with anticipated earnings growth of 9.5% for 2024 and 11% for 2025 [1] Financial Performance - The Technology & Analytics Solutions (TAS) segment saw a 4% revenue increase in Q2 2024, excluding COVID-19 impacts and foreign exchange effects, with expected TAS revenue growth of 6-7% for the second half of the year [2] - R&D Solutions (R&DS) recorded new bookings of approximately $2.7 billion and a record backlog of $30.6 billion, indicating strong future revenue potential [3] - Management expects total revenues for Q3 2024 to be between $3.83 billion and $3.88 billion, and for full-year 2024 to be in the range of $15.4 billion to $15.5 billion [4] - EPS for Q3 2024 is anticipated to range between $2.76 and $2.86 per share [4] Strategic Initiatives - The company is investing in AI and machine learning, leading to market-leading solutions that enhance operational efficiency and client engagement [5] - In Q2 2024, IQVIA contracted with a top 20 client to expand its commercial technology ecosystem, integrating AI and ML offerings into the client's infrastructure for better data management [6] Operational Challenges - The company faces challenges due to large pharmaceutical companies implementing cost-cutting measures, affecting pricing negotiations in both commercial and R&DS segments [6] - Operating expenses increased to $509 million in Q2 2024 from $482 million in Q2 2023, indicating rising costs [7] - The current ratio was 0.84 at the end of Q2 2024, suggesting potential difficulties in meeting short-term obligations [8]

In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth. Participation in global economies acts as a defense against economic difficulties at home and a pathway ...

Core Viewpoint - Investors are evaluating IQVIA Holdings (IQV) and Waters (WAT) for potential undervalued stock opportunities, with IQV currently appearing as the more favorable option based on various valuation metrics [1]. Valuation Metrics - IQV has a forward P/E ratio of 22.16, while WAT has a higher forward P/E of 25.97, indicating that IQV may be more attractively priced [3]. - The PEG ratio for IQV is 2.05, compared to WAT's PEG ratio of 4.90, suggesting that IQV's expected earnings growth is more reasonably priced [3]. - IQV holds a Value grade of B, while WAT has a Value grade of D, reflecting stronger estimate revision activity and more attractive valuation metrics for IQV [4]. Zacks Rank and Style Scores - IQV has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while WAT has a Zacks Rank of 4 (Sell) [2]. - The Zacks Rank system favors stocks with strong earnings estimate revisions, and combining this with a strong Value grade can help identify great value stocks [5]. Additional Valuation Comparisons - IQV's P/B ratio is 6.65, significantly lower than WAT's P/B ratio of 14.50, further indicating that IQV may be undervalued relative to its book value [6]. - The Value category of the Style Scores system utilizes various metrics, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, to assess a company's fair value [7].

Financial Performance - The Company reported net income of $363 million for the three months ended June 30, 2024, compared to $297 million for the same period in 2023, representing a 22.2% increase [130]. - Diluted earnings per share for the six months ended June 30, 2024, was $3.53, up from $3.12 for the same period in 2023, reflecting a 13.2% increase [130]. - Revenues for Q2 2024 increased by $86 million, or 2.3%, compared to Q2 2023, driven by a constant currency revenue growth of approximately $130 million, or 3.5% [143]. - For the first six months of 2024, revenues rose by $171 million, or 2.3%, compared to the same period in 2023, with constant currency growth of approximately $235 million, or 3.2% [144]. - Total revenues for the first six months of 2024 reached $7,551 million, compared to $7,380 million in the same period of 2023 [154]. - Net income for the six months ended June 30, 2024, was $262 million, significantly up from $86 million for the twelve months ended December 31, 2023 [240]. Debt and Cash Management - As of June 30, 2024, the total principal amount of debt was $13,328 million, a decrease from $13,752 million as of December 31, 2023 [112]. - The Company had $1,995 million of available borrowing capacity on its $2,000 million revolving credit facility as of June 30, 2024 [113]. - The total cash balance as of June 30, 2024, was $1,545 million, an increase from $1,376 million as of December 31, 2023 [229]. - Net cash provided by operating activities for the first six months of 2024 was $1,110 million, compared to $819 million in the same period of 2023 [220]. - Cash provided by operating activities increased by $291 million during the first six months of 2024 compared to the same period in 2023 [247]. - Cash used in investing activities decreased by $283 million during the first six months of 2024, primarily due to less cash used for acquisitions of businesses, which decreased by $223 million [248]. Operational Changes and Restructuring - The Company is undergoing restructuring actions to reduce overcapacity and align resources, expected to continue throughout 2024 and into 2025 [124]. - Restructuring costs for Q2 2024 amounted to $28 million, up from $20 million in Q2 2023 [147]. - Restructuring costs incurred during 2024 and 2023 are expected to continue throughout 2024 and into 2025, aimed at streamlining global operations and integrating acquisitions [188]. Segment Performance - The Company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions [129]. - Segment profit for Technology & Analytics Solutions was $361 million in Q2 2024, down from $370 million in Q2 2023 [154]. - Research & Development Solutions saw a segment profit increase to $493 million in Q2 2024, compared to $468 million in Q2 2023 [154]. - Research & Development Solutions' revenues for Q2 2024 were $2,147 million, an increase of $51 million, or 2.4%, compared to Q2 2023 [203]. - Contract Sales & Medical Solutions' revenues were $172 million in Q2 2024, a decrease of $4 million, or 2.3%, compared to Q2 2023 [211]. Expenses and Costs - Cost of revenues increased by $91 million for the first six months of 2024, with a constant currency increase of approximately $324 million, or 6.7% [145]. - Selling, general and administrative expenses rose by $27 million in Q2 2024, reflecting a constant currency increase of approximately $45 million, or 9.3% [146]. - Selling, general and administrative expenses for the six months ended June 30, 2024, increased by $22 million, or 2.2%, to $1,017 million from $995 million in 2023, maintaining 13.5% of revenues [167]. - The cost of revenues for Research & Development Solutions increased by $14 million, or 1.0%, in Q2 2024, with a constant currency increase of approximately $110 million, or 7.8% [205]. - Selling, general and administrative expenses for Research & Development Solutions rose by $12 million, or 5.7%, in Q2 2024, including a constant currency increase of approximately $16 million, or 7.6% [207]. Tax and Interest - The effective income tax rate for the first six months of 2024 was 16.0%, down from 20.6% in 2023, positively impacted by changes in the geographical mix of earnings [191]. - Interest expense for the six months ended June 30, 2024, was $329 million, an increase from $310 million in 2023, primarily due to higher base rate interest costs [170]. Acquisitions and Goodwill - The Company completed several individually immaterial acquisitions during the six months ended June 30, 2024, contributing to goodwill primarily from expected synergies and new customer relationships [121].